UPNEEQ® Eyelid Lifter

(oxymetazoline hydrochloride ophthalmic solution)

Meet Upneeq

Do you feel like your eyelids need a pick-me-up? Meet Upneeq – the only FDA-approved prescription eyedrop that lifts your upper eyelids and helps open your eyes for those with acquired ptosis (low-lying lids).

Upneeq logo

What can Upneeq do to help you?

Eyelids are lifted quickly, sometimes in as little as 2 hours.

  • 84% of patients in clinical trials had some form of improvement
  • 74% of patients had more than a 50% improvement rate

Upneeq can significantly improve your upper field of vision

  • 87.8% of patients had some form of improvement
  • 40.8% of patients had at least a 50% improvement on Day 14 (2 hours after applying Upneeq)

It’s also safe and patients tolerate it well

  • Upneeq was proven to be safe and effective in clinical trials when used as directed
  • Common side effects (seen in 1-5% of patients) included: eye inflammation, eye redness, dry eye, blurred vision, instillation site pain, eye irritation, and headache

Where can you get it? Call today to schedule your next eye exam at Switch Eye Center and speak with your ophthalmologist. Upneeq is only available with a prescription.

upneeq before and after photos
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.